Avadel Pharmaceuticals plc's latest marketcap:
As of 07/05/2025, Avadel Pharmaceuticals plc's market capitalization has reached $865.32 M. According to our data, Avadel Pharmaceuticals plc is the 10486th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 865.32 M |
| Revenue (ttm) | 194.45 M |
| Net Income (ttm) | -26,410,000 |
| Shares Out | 96.9 M |
| EPS (ttm) | -0.27 |
| Forward PE | 26.31 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/07/2025 |
Avadel Pharmaceuticals plc's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $865.32 M | -15.85% | 10486 |
| 12/31/2024 | $1.01 B | -20.13% | 8755 |
| 12/29/2023 | $1.27 B | 186.71% | 7472 |
| 12/30/2022 | $442.3 M | -6.63% | 13043 |
| 12/31/2021 | $473.7 M | 21.68% | 13709 |
| 12/31/2020 | $389.3 M | 37.71% | 13042 |
| 12/31/2019 | $282.7 M | 196.02% | 13054 |
| 12/31/2018 | $95.5 M | -70.71% | 17501 |
| 12/29/2017 | $326.1 M | -23.9% | 12514 |
| 12/30/2016 | $428.5 M | -12.68% | 9991 |
Company Profile
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc is a biopharmaceutical company based in the United States, focused on innovative therapies for sleep disorders and other medical conditions.
Key Product Candidate
LUMRYZ – A sodium oxybate formulation currently in Phase 3 clinical trials for treating:
- Cataplexy
- Excessive daytime sleepiness (EDS)
The therapy is being evaluated for patients aged seven and older with narcolepsy.
Company Background
Formerly known as Flamel Technologies SA, the company rebranded as Avadel Pharmaceuticals plc in January 2017. Founded in 2015, its headquarters are located in Dublin 2, Ireland.
Frequently Asked Questions
-
What is Avadel Pharmaceuticals plc's (AVDL) current market cap?As of 07/05/2025, Avadel Pharmaceuticals plc (including the parent company, if applicable) has an estimated market capitalization of $865.32 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Avadel Pharmaceuticals plc (AVDL) rank globally by market cap?Avadel Pharmaceuticals plc global market capitalization ranking is approximately 10486 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.